Arcturus Therapeutics, a US-based life sciences company working out of Janssen Labs, an incubator created by Janssen Research & Development (part of Johnson & Johnson), has raised $1.3m in a seed funding round led by multiple high net-worth private investors from the United States and Canada.
The new round of funding will support the purchase of capital equipment and further development of Arcturus’ intellectual property of ribonucleic acid interference (RNAi) delivery technologies, along with RNAi target selection, design and in vitro proof of concept studies.
Joseph Payne, president and chief executive officer, Arcturus, said:. “Arcturus is poised to contribute significant disruptive and promising treatments for rare diseases, contributing to improved quality of life and betterment of society.”
Arcturus Therapeutics was founded in 2013 by pharmaceutical scientists Joseph Payne and Pad Chivukula to pursue RNAi solutions for rare diseases.